litlas
Log inCreate account

William J. Gradishar

Active 1991–2025

139
Papers
27,414
Citations
80
h-index
129
i10-index

Citations

Citations per year for William J. Gradishar1991: 3 citations1992: 12 citations1993: 12 citations1994: 7 citations1995: 11 citations1996: 9 citations1997: 16 citations1998: 10 citations1999: 3 citations2000: 6 citations2001: 9 citations2002: 18 citations2003: 34 citations2004: 24 citations2005: 62 citations2006: 70 citations2007: 84 citations2008: 88 citations2009: 124 citations2010: 131 citations2011: 149 citations2012: 154 citations2013: 163 citations2014: 179 citations2015: 163 citations2016: 142 citations2017: 163 citations2018: 152 citations2019: 683 citations2020: 952 citations2021: 955 citations2022: 858 citations2023: 678 citations2024: 1,224 citations2025: 577 citations2026: 27 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,963 citing papers, 25.7% of this breakdownChina: 1,472 citing papers, 12.7% of this breakdownItaly: 694 citing papers, 6% of this breakdownGermany: 513 citing papers, 4.4% of this breakdownUnited Kingdom: 506 citing papers, 4.4% of this breakdownFrance: 404 citing papers, 3.5% of this breakdownCanada: 397 citing papers, 3.4% of this breakdownSpain: 355 citing papers, 3.1% of this breakdownSouth Korea: 272 citing papers, 2.4% of this breakdownSwitzerland: 266 citing papers, 2.3% of this breakdownAustralia: 262 citing papers, 2.3% of this breakdownIndia: 260 citing papers, 2.2% of this breakdown
0%25.7%Other 27.6%

Institutions

Fields

  • Medicine54.5%
  • Biochemistry, Genetics and Molecular Biology30.6%
  • Materials Science4.5%
  • Health Professions2.2%
  • Immunology and Microbiology1.9%
  • Computer Science1.7%
  • Other4.6%

Topics

  • Breast Cancer Treatment Studies7.6%
  • HER2/EGFR in Cancer Research5.3%
  • Advanced Breast Cancer Therapies4.5%
  • Cancer Treatment and Pharmacology3.5%
  • Cancer Genomics and Diagnostics2.4%
  • Nanoparticle-Based Drug Delivery2.3%
  • Other74.4%

Coauthors

All papers

Open in search
  1. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Bethany Anderson, Harold J. Burstein, Helen K. Chew, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice A. Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2022 cited by 964

  2. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

    Authors: Harold J. Burstein, Giuseppe Curigliano, Beat Thürlimann, William P. Weber, Philip Poortmans, Meredith M. Regan, H.-J. Senn, Eric P. Winer, Michael Gnant, Stephan Aebi, Fabrice André, Carlos Barrios, Jonas Bergh, Hervé Bonnefoi, Denisse Bretel Morales, Sara Y. Brucker, Harold J. Burstein, David Cameron, Fátima Cardoso, Lisa A. Carey, Boon Chua, Eva Ciruelos, Marco Colleoni, Giuseppe Curigliano, Suzette Delaloge, Carsten Denkert, Peter Dubsky, Bent Ejlertsen, Florian Fitzal, Prudence A. Francis, Viviana Galimberti, Hebatallah Gamal El Din Mohamed Mahmoud, Judy E. Garber, Michael Gnant, William J. Gradishar, Bahadır M. Güllüoğlu, Nadia Harbeck, Chiun‐Sheng Huang, Jens Huober, André Ilbawi, Zefei Jiang, Steven Johnston, Eun Sook Lee, Sibylle Loibl, Monica Morrow, Ann H. Partridge, Martine Piccart, Philip Poortmans, Aleix Prat, Meredith M. Regan, Isabella Rubio, Hope S. Rugo, Emiel J. Rutgers, Felix Sedlmayer, Vladimir Semiglazov, Hans-Joerg Senn, Zhiming Shao, Tanja Španić, Petra Tesařová, Beat Thürlimann, Sergei Tjulandin, Masakazu Toi, Maureen Trudeau, Nicholas Turner, Inez Vaz Luis, Giuseppe Viale, Toru Watanabe, William P. Weber, Eric P. Winer, Binghe Xu - Annals of Oncology 2021 cited by 803

  3. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

    Authors: William J. Gradishar, Meena S. Moran, Jame Abraham, Vandana G. Abramson, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Bethany Anderson, Harold J. Burstein, Helen K. Chew, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, A. Marilyn Leitch, Janice A. Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Bryan P. Schneider, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, Mei Wei, Kari B. Wisinski, Jessica Young, Kay T. Yeung, Mary A. Dwyer, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2023 cited by 440

  4. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    Authors: William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice A. Lyons, P. Kelly Marcom, Jennifer M. Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2020 cited by 1,618

  5. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

    Authors: Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng, Ming‐Shen Dai, Shang-Wen Chen, Sara A. Hurvitz, Sung‐Bae Kim, Beverly Moy, Suzette Delaloge, William J. Gradishar, Norikazu Masuda, Markéta Palácová, Maureen Trudeau, Johanna Mattson, Yoon Sim Yap, Ming‐Feng Hou, Michelino De Laurentiis, Yu‐Min Yeh, Hong‐Tai Chang, Thomas Yau, Hans Wildiers, Barbara Haley, Daniele Fagnani, Yen‐Shen Lu, John Crown, Johnson Lin, Masato Takahashi, Toshimi Takano, Miki Yamaguchi, Takaaki Fujii, Bin Yao, Judith D. Bebchuk, Kiana Keyvanjah, Richard Bryce, Adam Brufsky, for the NALA Investigators - Journal of Clinical Oncology 2020 cited by 609

  6. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

    Authors: William J. Gradishar, Meena S. Moran, Jame Abraham, Vandana G. Abramson, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Bethany Anderson, Janet E. Bailey, Harold J. Burstein, Nan Chen, Helen K. Chew, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, A. Marilyn Leitch, Janice A. Lyons, Susie McCloskey, Melissa McShane, Joanne Mortimer, Sameer A. Patel, Laura H. Rosenberger, Hope S. Rugo, Cesar A. Santa‐Maria, Bryan P. Schneider, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, Mei Wei, Kari B. Wisinski, Kay T. Yeung, Jessica Young, Ryan Schonfeld, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2024 cited by 560

  7. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

    Authors: William J. Gradishar, Sergei Tjulandin, Neville Davidson, Heather Shaw, Neil Desai, Paul Bhar, Michael Hawkins, Joyce O’Shaughnessy - Journal of Clinical Oncology 2005 cited by 2,132

  8. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

    Authors: Kevin Kalinsky, Melissa Accordino, Codruța Chiuzan, Prabhjot S. Mundi, Elizabeth Sakach, Claire Sathe, Heejoon Ahn, Meghna S. Trivedi, Yelena Novik, Amy Tiersten, George Raptis, Lea Baer, Sun Young Oh, Amelia Zelnak, Kari B. Wisinski, Eleni Andreopoulou, William J. Gradishar, Erica Stringer-Reasor, Sonya Reid, Anne O’Dea, Ruth O’Regan, Katherine D. Crew, Dawn L. Hershman - Journal of Clinical Oncology 2023 cited by 191

  9. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Authors: Giuseppe Curigliano, Harold J. Burstein, Michael Gnant, Sibylle Loibl, David Cameron, Meredith M. Regan, Carsten Denkert, Philip Poortmans, William P. Weber, Beat Thürlimann, Stefan Aebi, Meteb Al‐Foheidi, Fabrice André, Mykola Anikusko, R. Badwe, A.V. Barrio, Carlos H. Barrios, Jonas Bergh, Hervé Bonnefoi, Daniela Morales, Sara Y. Brucker, Harold J. Burstein, Carlos Caldas, David Cameron, F. Cardoso, Maria João Cardoso, L.A Carey, Stephen Chia, Charlotte E. Coles, J. Cortes, Giuseppe Curigliano, Jana de Boniface, Suzette Delaloge, A. DeMichele, Carsten Denkert, Gerd Fastner, Florian Fitzal, Prudence A. Francis, H Gamal, Oreste ­Gentilini, Michael Gnant, William J. Gradishar, B. Gulluoglu, Nadia Harbeck, Jörg Heil, Chien Shiun Huang, Jens Huober, Zeping Jiang, Orit Kaidar‐Person, Marleen Kok, Eun‐So Lee, Sherene Loi, S. Loibl, Miguel Martín, Icro Meattini, Monica Morrow, A. H. Partridge, Frédérique Penault‐Llorca, Martine Piccart, Lori J. Pierce, Philip Poortmans, Meredith M. Regan, J. S. Reis-Filho, Isabel T. Rubio, Hope S. Rugo, Emiel J. Rutgers, Cristina Saura, Elżbieta Senkus, Zhi-Ming Shao, Christian F. Singer, Tanja Španič, Beat Thuerlimann, Masakazu Toi, Sara M. Tolaney, Nicholas C. Turner, Andrew Tutt, M.-J. Vrancken Peeters, Toru Watanabe, William P. Weber, Hans Wildiers, B. Xu - Annals of Oncology 2023 cited by 221

  10. Albumin-bound paclitaxel: a next-generation taxane

    Authors: William J. Gradishar - Expert Opinion on Pharmacotherapy 2006 cited by 708

  11. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

    Authors: Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, Javier Cortés, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Christelle Lévy, Ursa Brown‐Glaberman, Jean-­Marc Ferrero, Maaike de Boer, Sung‐Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik Jakobsen, Bella Kaufman, Rinat Yerushalmi, Peter A. Fasching, Jeffrey L. Nordstrom, Ezio Bonvini, Scott Koenig, Sutton Edlich, Shengyan Hong, Edwin P. Rock, William J. Gradishar, SOPHIA Study Group - JAMA Oncology 2021 cited by 349

  12. Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

    Authors: Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley, Janice F. Eakle, Lee S. Schwartzberg, Joyce O’Shaughnessy, William J. Gradishar, Peter Schmid, Eric P. Winer, Catherine M. Kelly, Rita Nanda, Ayca Gucalp, Ahmad Awada, Laura García‐Estévez, Maureen Trudeau, Joyce Steinberg, Hirdesh Uppal, Iulia Cristina Tudor, Amy Peterson, Javier Cortés - Journal of Clinical Oncology 2018 cited by 519

  13. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

    Authors: Ricardo Costa, Hyo S. Han, William J. Gradishar - Breast Cancer Research and Treatment 2018 cited by 455

  14. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

    Authors: Fátima Cardoso, Shani Paluch–Shimon, Eva Schumacher-Wulf, Leonor Vasconcelos de Matos, Karen A. Gelmon, Matti Aapro, Jyoti Bajpai, Carlos H. Barrios, Jonas Bergh, Elizabeth Bergsten-Nordström, Laura Biganzoli, Maria João Cardoso, Lisa A. Carey, Mariana Chávez‐MacGregor, Runcie C.W. Chidebe, Javier Cortés, Giuseppe Curigliano, Rebecca Dent, Nagi S. El Saghir, Alexandru Eniu, Lesley Fallowfield, Prudence A. Francis, Sandra X. Franco Millan, Jenny Gilchrist, Joseph Gligorov, William J. Gradishar, Renate Haidinger, Nadia Harbeck, Xichun Hu, Ranjit Kaur, Belinda E. Kiely, Sungbae Kim, Smruti Koppikar, Marion Kuper‐Hommel, Frédéric Lecouvet, Ginny Mason, Shirley Mertz, Volkmar Müller, Claire Myerson, Silvia P. Neciosup, Birgitte Vrou Offersen, Shinji Ohno, Olivia Pagani, Ann H. Partridge, Frédérique Penault‐Llorca, Aleix Prat, Hope S. Rugo, Elżbieta Senkus, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Daniel Vorobiof, Peter Vuylsteke, Theresa Wiseman, Binghe Xu, Alberto Costa, Larry Norton, Eric P. Winer - The Breast 2024 cited by 197

  15. Role of Fcγ receptors in HER2-targeted breast cancer therapy

    Authors: Antonino Musolino, William J. Gradishar, Hope S. Rugo, Jeffrey L. Nordstrom, Edwin P. Rock, Fernanda I. Arnaldez, Mark D. Pegram - Journal for ImmunoTherapy of Cancer 2022 cited by 125

  16. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

    Authors: Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, Javier Cortés, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N. Schwartz, Timothy Pluard, Francesco Ricci, William R. Gwin, Christelle Lévy, Ursa Brown‐Glaberman, Jean-­Marc Ferrero, Maaike de Boer, Sung‐Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik Jakobsen, Einav Nili Gal‐Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar, on behalf of the SOPHIA Study Group - Journal of Clinical Oncology 2022 cited by 80

  17. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Authors: Marc L. Citron, Donald A. Berry, Constance Cirrincione, Clifford A. Hudis, Eric P. Winer, William J. Gradishar, Nancy E. Davidson, Silvana Martino, Robert B. Livingston, James N. Ingle, Edith A. Perez, John T. Carpenter, David D. Hurd, James F. Holland, Barbara L. Smith, Carolyn I. Sartor, Eleanor H. Leung, Jeffrey S. Abrams, Richard L. Schilsky, Hyman B. Muss, Larry Norton - Journal of Clinical Oncology 2003 cited by 1,564

  18. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

    Authors: R. Charles Coombes, Sacha J. Howell, Simon Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea Chap, Paul Richards, William J. Gradishar, Sagar Sardesai, Jason M. Melear, Joyce O’Shaughnessy, Patrick J. Ward, Pavani Chalasani, Hendrik‐Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew Krebs - Nature Communications 2023 cited by 57

  19. ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

    Authors: Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac García-Murillas, Aman U. Budzar, J.F.R. Robertson, William J. Gradishar, Martine Piccart, Gaia Schiavon, Judith M. Bliss, Mitch Dowsett, Stephen Johnston, Stephen Chia - Clinical Cancer Research 2020 cited by 158

  20. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

    Authors: Sarika Jain, Ami N. Shah, Cesar A. Santa‐Maria, Kalliopi P. Siziopikou, Alfred Rademaker, Irene Helenowski, Massimo Cristofanilli, William J. Gradishar - Breast Cancer Research and Treatment 2018 cited by 152

  21. NCCN Guidelines Insights: Breast Cancer, Version 1.2017

    Authors: William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice A. Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth Reed, Kilian Salerno, Lee S. Schwartzberg, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Dorothy A. Shead, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2017 cited by 542

  22. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

    Authors: William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice A. Lyons, Jennifer M. Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica Young, Jennifer L. Burns, Rashmi Kumar - Journal of the National Comprehensive Cancer Network 2021 cited by 351

  23. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE

    Authors: Stephen Johnston, Roberto Hegg, Seock‐Ah Im, In Hae Park, Olga Burdaeva, G. Kurteva, Michael F. Press, Sergei Tjulandin, Hiroji Iwata, Sérgio D. Simon, Sarah Kenny, Séverine Sarp, Miguel Izquierdo, Lisa S. Williams, William J. Gradishar - Journal of Clinical Oncology 2020 cited by 126

  24. Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer

    Authors: Nurmaa K. Dashzeveg, Yuzhi Jia, Youbin Zhang, Lorenzo Gerratana, Priyam Patel, Asif Shajahan, Tsogbadrakh Dandar, Erika K. Ramos, Hannah F. Almubarak, Valery Adorno-Cruz, Rokana Taftaf, Emma J. Schuster, David Scholten, Michael T. Sokolowski, Carolina Reduzzi, Lamiaa El-Shennawy, Andrew D. Hoffmann, Maroua Manai, Qiang Zhang, Paolo D’Amico, Parastoo Azadi, Karen Colley, Leonidas C. Platanias, Ami N. Shah, William J. Gradishar, Massimo Cristofanilli, William A. Müller, Brian A. Cobb, Huiping Liu - Cancer Discovery 2023 cited by 57